Superworth

10x Genomics price to free cash flow TXG

Market value divided by free cash flow over the last twelve months, since 2024.

Today, Nov 2, 2026
66.1×
2-year median
31.3×
Against its 2-year history
76th
percentile: 0 is its lowest day, 100 its highest
2-year range
17.8× to 100×
Peer median
25.6×

10x Genomics' price to free cash flow is 66.1× as of Nov 2, 2026.

That is above its 2-year median of 31.3×, higher than on 76% of days in the last 2 years.

Over that time it ranged from 17.8× in Feb 2026 to 100× in Oct 2026.

The median for 10 diagnostics and research stocks of a similar size is 25.6×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far66.1×17.8×100×
202525.6×22.2×72.5×
202467.8×62.0×75.9×

Against its peers

Companies in Medical - Diagnostics & Research nearest 10x Genomics' size, closest first, today.

CompanyPrice to free cash flow
TXG10x Genomics66.1×
CAICaris Life Sciences73.2×
BIOBio-Rad Laboratories27.7×
LNTHLantheus16.9×
BLLNBillionToOne157×
CDNACareDxn/m
VCYTVeracyte23.7×
RVTYRevvity30.3×
MEDPMedpace25.6×
DGXQuest Diagnostics20.0×
LHLabcorp25.0×
Peer median25.6×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on 10x Genomics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.